S Kumari1, P Kumar2, M Kumar3, S Singh4, G Narayan1. 1. Cancer Genetics Laboratory, Department of Molecular and Human Genetics, Faculty of Science, Banaras Hindu University, Varanasi, 221005, India. 2. Department of Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi, 221005, India. puneetimsbhu@gmail.com. 3. Department of Pathology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, 221005, India. 4. Department of Zoology, Banaras Hindu University, Mahila Mahavidyalaya, Varanasi, 221 005, India.
Abstract
BACKGROUND: Deregulated expression of cell cycle regulators p27 and p16 is associated with cancer progression. p27kip1 and p16INKa are a cyclin dependent kinase inhibitor whose major target is the cyclinE/CDK2 and cyclinD/CDK4/6 complex, respectively, that governs cell cycle transition from late G1 to S phase. METHODS: We recruited biopsies of a total of 84 subjects including 72 primary tumor biopsies from histopathologically proven gastric carcinoma, 8 adjacent controls and 12 independent controls. We used gastric cancer cell line, AGS, for validation of our data. Expression profiling at transcript level was done by semi-quantitative RT-PCR and at proteome level by immunohistochemistry and immunofluorescence. Receiver operator characteristics analysis was done for determining the diagnostic utility of p27 and p16 with respect to the sensitivity and specificity. RESULTS: We demonstrate that p27 and p16 are frequently over expressed in early stages of gastric carcinoma. Our semi-quantitative data show a significant upregulation of p27 (Mean ± SEM, 0.4771 ± 0.0895; p = 0.0001) and p16 (Mean ± SEM, 0.4676 ± 0.04305; p = 0.0001) at mRNA level. Concordant to semi-quantitative data, immunohistochemistry data also showed a significant upregulation of p27 (Mean ± SEM, 196.4 ± 10.84; p < 0.0001) and p16 (Mean ± SEM, 100.4 ± 23.71; p < 0.0001) at protein level. CONCLUSIONS: The present study showed that the significant upregulation of p27 and p16 were associated with early events in gastric carcinogenesis. Our data suggests that clinical correlation of these differentially expressed genes may be useful as diagnostic biomarkers for early detection of gastric carcinoma and promising therapeutics target for GC patients.
BACKGROUND: Deregulated expression of cell cycle regulators p27 and p16 is associated with cancer progression. p27kip1 and p16INKa are a cyclin dependent kinase inhibitor whose major target is the cyclinE/CDK2 and cyclinD/CDK4/6 complex, respectively, that governs cell cycle transition from late G1 to S phase. METHODS: We recruited biopsies of a total of 84 subjects including 72 primary tumor biopsies from histopathologically proven gastric carcinoma, 8 adjacent controls and 12 independent controls. We used gastric cancer cell line, AGS, for validation of our data. Expression profiling at transcript level was done by semi-quantitative RT-PCR and at proteome level by immunohistochemistry and immunofluorescence. Receiver operator characteristics analysis was done for determining the diagnostic utility of p27 and p16 with respect to the sensitivity and specificity. RESULTS: We demonstrate that p27 and p16 are frequently over expressed in early stages of gastric carcinoma. Our semi-quantitative data show a significant upregulation of p27 (Mean ± SEM, 0.4771 ± 0.0895; p = 0.0001) and p16 (Mean ± SEM, 0.4676 ± 0.04305; p = 0.0001) at mRNA level. Concordant to semi-quantitative data, immunohistochemistry data also showed a significant upregulation of p27 (Mean ± SEM, 196.4 ± 10.84; p < 0.0001) and p16 (Mean ± SEM, 100.4 ± 23.71; p < 0.0001) at protein level. CONCLUSIONS: The present study showed that the significant upregulation of p27 and p16 were associated with early events in gastric carcinogenesis. Our data suggests that clinical correlation of these differentially expressed genes may be useful as diagnostic biomarkers for early detection of gastric carcinoma and promising therapeutics target for GC patients.
Authors: Masoud Babaei; Farhad Pourfarzi; Abbas Yazdanbod; Mir Mehdi Chiniforush; Mohammad Hassan Derakhshan; Seyed Mohsen Mousavi; Fatemeh Samadi; Giti Rahimi Journal: Asian Pac J Cancer Prev Date: 2010
Authors: S P Singh; J Lipman; H Goldman; F H Ellis; L Aizenman; M G Cangi; S Signoretti; D S Chiaur; M Pagano; M Loda Journal: Cancer Res Date: 1998-04-15 Impact factor: 12.701
Authors: S Kulkarni; J S Rader; F Zhang; H Liapis; A T Koki; J L Masferrer; K Subbaramaiah; A J Dannenberg Journal: Clin Cancer Res Date: 2001-02 Impact factor: 12.531
Authors: P Tan; B Cady; M Wanner; P Worland; B Cukor; C Magi-Galluzzi; P Lavin; G Draetta; M Pagano; M Loda Journal: Cancer Res Date: 1997-04-01 Impact factor: 12.701
Authors: V Masciullo; A Sgambato; C Pacilio; B Pucci; G Ferrandina; J Palazzo; A Carbone; A Cittadini; S Mancuso; G Scambia; A Giordano Journal: Cancer Res Date: 1999-08-01 Impact factor: 12.701
Authors: Márk Híveš; Jana Jurečeková; Ján Kliment; Marián Grendár; Peter Kaplán; Róbert Dušenka; Daniel Evin; Marta Vilčková; Klaudia Híveš Holečková; Monika Kmeťová Sivoňová Journal: Cancer Genomics Proteomics Date: 2022 May-Jun Impact factor: 4.069